Gastric Cancer Open Access
Copyright ©2005 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 7, 2005; 11(17): 2545-2548
Published online May 7, 2005. doi: 10.3748/wjg.v11.i17.2545
Dynamic expression of pepsinogen C in gastric cancer, precancerous lesions and Helicobacter pylori associated gastric diseases
Pei-Fang Ning, Hui-Jie Liu, Yuan Yuan, Cancer Institute of the First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China
Author contributions: All authors contributed equally to the work.
Correspondence to: Dr. Yuan Yuan, Cancer Institute of the First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China. yyuan@mail.cmu.edu.cn
Telephone: +86-24-23256666-6153
Received: March 19, 2004
Revised: March 20, 2004
Accepted: April 13, 2004
Published online: May 7, 2005

Abstract

AIM: To investigate the relationship between the expression of pepsinogen C (PGC) and gastric cancer, precancerous diseases, and Helicobacter pylori (H pylori) infection.

METHODS: The expression of PGC was determined by immunohistochemistry method in 430 cases of gastric mucosa. H pylori infection was determined by HE staining, PCR and ELISA in 318 specimens.

RESULTS: The positive rate of PGC expression in 54 cases of normal gastric mucosa was 100%. The positive rates of PGC expression in superficial gastritis or gastric ulcer or erosion, atrophic gastritis or gastric dysplasia and gastric cancer decreased significantly in sequence (P<0.05; 100%/89.2% vs 14.3%/15.2% vs 2.4%). The over-expression rate of PGC in group of superficial gastritis with H pylori infection was higher than that in group without H pylori infection (P<0.05; χ2 = 0.032 28/33 vs 15/25). The positive rate of PGC expression in group of atrophic gastritis with H pylori infection was lower than that in group without H pylori infection (P <0.01; χ2 = 0.003 4/61 vs 9/30), and in dysplasia and gastric cancer.

CONCLUSION: The level of PGC expression has a close relationship with the degree of malignancy of gastric mucosa and development of gastric lesions. There is a relationship between H pylori infection and expression of antigen PGC in gastric mucosa, the positive rate of PGC expression increases in early stage of gastric lesions with H pylori infection such as gastric inflammation and decreases during the late stage such as precancerous diseases and gastric cancer. PGC-negative cases with H pylori-positive gastric lesions should be given special attention.

Key Words: H pylori; Pepsinogen C; Gastric cancer



INTRODUCTION

Pepsinogen (PG) is the precursor of pepsin or gastricsin and activated in acid condition. Pepsin of humans can be divided into two groups: pepsinogen A (PGA) and pepsinogen C (PGC)[1]. PGA is mainly distributed in gastric fundus and PGC throughout the stomach and proximal duodenum. PGC is mainly secreted by chief cells of gastric gland, also by cardiac gland and pyloric gland and Brunner gland. The change of serum PGC can reflect the degree of gastric lesions or differentiation of gastric cells[2,3]. Recently studies showed that the change of PGC could reflect the degree of gastric disease and differentiation[4-7]. The level of PGC and the ratio of PGA/PGC in serum decreased in chronic atrophic gastritis and gastric cancer. There is now evidence from epidemiological studies that Helicobacter pylori (H pylori) carriers have a significantly greater risk of developing gastric cancer[8-10]. H pylori has been classified as a group I carcinogen by IARC, but the exact role H pylori plays is unclear. In the present study, we investigate the dynamic expression of PGC antigen in gastric cancer and precancerous lesions and H pylori-associated gastric lesions and evaluate the application value of PGC in gastric cancer diagnosis, and also the influence of H pylori on PGC antigen expression.

MATERIALS AND METHODS
Samples

A total of 430 gastric mucosal biopsied specimens were involved in this study which came from the endoscopic screening of subjects in the region of Zhuanghe, Liaoning Province, a high risk area of gastric cancer from 1997 to 2002. Each of the biopsies contained gastric corpus, antrum and angulus and was diagnosed by two pathologists separately, including 54 cases of normal gastric mucosa, 58 cases of superficial gastritis, 37 cases of gastric ulcer or erosion, 91 cases of atrophic gastritis (all with intestinal metaplasia), 66 cases of dysplasia, and 124 cases of gastric cancer. There was no significant difference between normal and disease groups in age and sex (P>0.05).

Reagents

The anti-PGC antibody was a gift from Japanese Clinical Inspection Institute. The two-step SP kit (Lot No: Kit-9801D2) was a product of Maxin Company in Fujian, China; ELISA kit was from Huamei Company; and H pylori-DNA-PCR kit was from Fuhua Company in Shanghai, China.

H pylori examination

H pylori infection was detected by HE staining, PCR and ELISA. H pylori was considered positive if two of the three methods were positive. H pylori could be found in the gastric pit and mucus by histological examination. Detection of H pylori with H pylori-DNA PCR method followed the protocol of the kit. The bands in the same position as positive controls were defined as positive. When ELISA was performed, the samples with A value/A average value of negative controls ≥2.1 were defined as positive.

Immunohistochemistry staining of pepsinogen C

SP-two step immunostaining was performed according to the instructions of the kit. Diagnosis was made based on brown coloration with varied intensities and the number of cells stained brown[11]. Intensities of staining in cytoplasm were graded as score 1: light brown; score 2: brown; score 3: deep brown. The number of positively stained cells in total cells was categorized as score 1: stained cells<30%; score 2: stained cells 30-70%; score 3: stained cells >70%. According to the sum of the two indexes, the comprehensive scores were made. Comprehensive score 0 was defined as negative expression (-), comprehensive scores 2-3 as weakly positive expression (+), comprehensive score 4 as moderately positive expression (++), comprehensive scores 5-6 as strongly positive expression (+++). The cases with scores greater than 4 were defined as overexpression.

Statistical analysis

The data were analyzed by χ2 test. P values less than 0.05 were considered statistically significant.

RESULTS
Dynamic expression of pepsinogen C antigen in different gastric mucosal tissues

The PGC antigen was mainly expressed in plasma and nuclei. The positive rate of PGC expression in normal gastric mucosa and superficial gastritis was 100% (Figure 1A). All the atrophic gastritis mucosae were accompanied with intestinal metaplasia (IM) in which PGC was all negative, while the positive rate of PGC expression was 14.3% in atrophic gastritis in the area of non IM. The positive rates of PGC expression decreased in sequence of superficial gastritis, gastric ulcer or erosion, atrophic gastritis or gastric dysplasia and gastric cancer (P<0.05) (Figure 1B) and decreased significantly from superficial gastritis or gastric ulcer to atrophic gastritis or gastric dysplasia (P<0.01) (Table 1). The over-expression rates decreased significantly in sequence of normal gastric mucosa, superficial gastritis, gastric ulcer or erosion, atrophic gastritis or gastric dysplasia or gastric cancer (P<0.05).

Table 1 Expression of PGC antigen in various gastric lesions.
Gastric lesionsnNumber of cases with PGC expression
Positive rate (%)Over-expressionrate (%)
-++++++
Normal gastric mucosa54011439100.0b98.2b
Superficial gastritis580152617100.0b74.1bdf
Gastric ulcer or erosion3742013089.2abc35.1bcd
Atrophic gastritis9179111014.3bdf1.1df
Intestinal metaplasia91910000.0dfh0.0af
Dysplasia665691015.2bdf1.5df
Gastric cancer1241213002.4df0.0df
Figure 1
Figure 1 Expression of PGC in different gastric tissues. A: Positive expression of PGC in normal gastric mucosa (SP×100); B: Negative expression of PGC in gastric cancer (SP×400); C: Negative expression of PGC in atrophic gastritis with H pylori infection (SP×200).

The positive rate of PGC expression in well-differentiated gastric cancer was 9.4% and 0% in moderately or poorly-differentiated gastric cancer (P<0.05) (Table 2).

Table 2 Expression of PGC antigen in different histopathologic types of gastric cancer.
Histopathologic type of gastric cancernNo. of cases with PGC expressionPositive rate (%)
Well-differentiated3239.4
Moderately-differentiated3100.0
Poorly-differentiated6100.0a
Expression of PGC antigen in H pylori-associated gastric diseases

On examination, H pylori infection was detected in 318 cases of different gastric mucosa tissues in which 192 cases were H pylori-positive and 126 cases H pylori-negative. The positive rate of PGC expression was 100% in superficial gastritis but the over-expression rate was higher in H pylori-positive group than in H pylori-negative group (P<0.05). The PGC positive rate was higher in H pylori-positive group than in H pylori-negative group in the area of non IM in atrophic gastritis (P<0.01) (Figure 1C) and lower in groups of dysplasia and gastric cancer (P>0.05) (Table 3).

Table 3 Expression of PGC in H pylori-associated gastric lesions.
astric lesionsnH pylori positive
nH pylori negative
PGC positive expression
PGC over-expression
PGC positive expression
PGC over-expression
nRate (%)nRate (%)nRate (%)nRate (%)
Superficial gastritis3333100.02884.82525100.01560.0a
Atrophic gastritis6146.600.030930.0b13.3
Intestinalmetaplasia6100.000.03000.000
Dysplasia40410.002.519631.600.0
Gastric cancer5800.000.05235.800
DISCUSSION

PGC is known as progastricsin and a mature marker of stomach cells, the change of which could reflect the degree of gastric lesions[6,7]. In our study, the expression of PGC antigen was various in different gastric diseases. The positive rate of PGC expression was 100% in normal gastric mucosa and 2.4% in gastric cancer. The positive rates of PGC expression decreased gradually in sequence of benign lesions, precancerous lesions and gastric cancer, especially from benign lesions to precancerous lesions. We found that PGC antigen was negative in most of dysplasia and gastric cancer mucosae while in all of intestinal metaplasia mucosa there was no production of PGC. Zhang et al[12], found the adult residents with serum PG level abnormality were accompanied with a higher risk of precancerous lesions (intestinal metaplasia and epithelia dysplasia) in gastric mucosa than those with normal serum PG level during following-up. PGC served as a proteinase involved in the digestion of proteins in the stomach, its levels significantly decreased in atrophic gastritis and dysplasia implicating poorly differentiated cells in these two precancerous diseases and were more susceptible to gastric cancer, but the PGC levels of the above two lesions were still higher than those in gastric cancer (P<0.01). The dynamic expression of PGC in different gastric mucosa implicated that PGC antigen had a close relationship with malignancy of gastric mucosa and could well recognize benign or malignant gastric lesions. We also found the positive rate of PGC antigen in well-differentiated gastric cancer was higher than that of moderately or poorly-differentiated gastric cancer, showing PGC expression had some tendency toward a certain histopathologic type. The presence of PGC in cancer cells implicated some mature secreting function in them. The decrease of PGC expression indicated dedifferentiation or malignancy of cancer cells, and was also closely related with prognosis and metastasis[13-15].

The cause of gastric cancer is still unclear but it is generally considered as a multifactor process. H pylori infection is an important factor in the pathogenesis of gastric cancer. Most atrophic gastritis are related with H pylori infection. Epidemiological data showed H pylori carriers had a 2.8 to 6.0 fold increased risk of developing gastric cancer when compared with their H pylori-negative counterparts[16,17]. H pylori has been known as a group I carcinogen[7] and acts as the initiating agent[18,19]. It is still unclear whether H pylori plays a role in the development of atrophic gastritis and intestinal metaplasia.

In our study, the overexpression rate of PGC was higher in H pylori-positive superficial gastritis than in H pylori-negative cases. This is consistent with serological researches[5,20]. The level of PGC was proportional to the planting density of H pylori and decreased after H pylori eradication[21,22]. Possible explanations were[23-26]: H pylori infection could induce the expression of PG gene, the cytokines produced by H pylori-associated gastritis such as TNFα and lipopolysaccharide could stimulate chief cells to secrete PGC, H pylori infection could increase gastric acid and gastrin while decreasing somatostatin, all of which could increase PG level. The PG released into gastric lumen was activated to pepsin, which can damage gastric mucosa, aggravate gastritis and gastric ulcer. We also found the positive rate of PGC expression in H pylori-positive atrophic gastritis was lower than that in H pylori-negative cases (P<0.01) and the same trend presented in dysplasia and gastric cancer. One possible explanation was that the cytotoxin and immunoinflammation response induced by H pylori stimulated carcinogens such as oxygen-free radical and superoxide, which can accelerate mutations of PG gene and indirectly reduce the expression of PGC antigen, affecting the balance between cell proliferation, differentiation and apoptosis, and increasing the risk of developing gastric cancer[27-29].

In conclusion, the positive rate of PGC antigen increases in H pylori-related gastritis and decreases in H pylori-related atrophic gastritis, dysplasia and gastric cancer, the latter should be followed up closely to improve the early detection, evaluation of recurrence and prognosis of gastric cancer.

Footnotes
References
1.  Foster C, Aktar A, Kopf D, Zhang P, Guttentag S. Pepsinogen C: a type 2 cell-specific protease. Am J Physiol Lung Cell Mol Physiol. 2004;286:L382-L387.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 41]  [Cited by in F6Publishing: 43]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
2.  Korstanje A, den Hartog G, Biemond I, Lamers CB. The serological gastric biopsy: a non-endoscopical diagnostic approach in management of the dyspeptic patient: significance for primary care based on a survey of the literature. Scand J Gastroenterol Suppl. 2002;236:22-26.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 29]  [Cited by in F6Publishing: 38]  [Article Influence: 1.8]  [Reference Citation Analysis (0)]
3.  Kageyama T, Ichinose M, Tsukada-Kato S, Omata M, Narita Y, Moriyama A, Yonezawa S. Molecular cloning of neonate/infant-specific pepsinogens from rat stomach mucosa and their expressional change during development. Biochem Biophys Res Commun. 2000;267:806-812.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 37]  [Cited by in F6Publishing: 40]  [Article Influence: 1.7]  [Reference Citation Analysis (0)]
4.  Broutet N, Plebani M, Sakarovitch C, Sipponen P, Mégraud F. Pepsinogen A, pepsinogen C, and gastrin as markers of atrophic chronic gastritis in European dyspeptics. Br J Cancer. 2003;88:1239-1247.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 90]  [Cited by in F6Publishing: 99]  [Article Influence: 4.7]  [Reference Citation Analysis (0)]
5.  Miki K. Serum pepsinogen test for the diagnosis of stomach cancer. Nihon Rinsho. 2001;59 Suppl 4:204-207.  [PubMed]  [DOI]  [Cited in This Article: ]
6.  Fahey MT, Hamada GS, Nishimoto IN, Kowalski LP, Iriya K, Gama-Rodrigues JJ, Tsugane S. Ethnic differences in serum pepsinogen levels among Japanese and non-Japanese Brazilian gastric cancer patients and controls. Cancer Detect Prev. 2000;24:564-571.  [PubMed]  [DOI]  [Cited in This Article: ]
7.  Dinis-Ribeiro M, Lopes C, da Costa-Pereira A, Guilherme M, Barbosa J, Lomba-Viana H, Silva R, Moreira-Dias L. A follow up model for patients with atrophic chronic gastritis and intestinal metaplasia. J Clin Pathol. 2004;57:177-182.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 67]  [Cited by in F6Publishing: 76]  [Article Influence: 3.8]  [Reference Citation Analysis (0)]
8.  Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WH, Yuen ST, Leung SY. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004;291:187-194.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1015]  [Cited by in F6Publishing: 995]  [Article Influence: 49.8]  [Reference Citation Analysis (0)]
9.  Lu XL, Qian KD, Tang XQ, Zhu YL. Distribution of H.pylori antigens in gastric mucosa and its significance. J Zhejiang Univ Sci. 2004;5:242-245.  [PubMed]  [DOI]  [Cited in This Article: ]
10.  International Agency for Research of Cancer Monographs on the Evaluation of Carcinogenic Risks to Humans Infection with Helicobacter pylori. Vol 61. Lyon: IARC Scientific Publications 1994; 177-240.  [PubMed]  [DOI]  [Cited in This Article: ]
11.  Filipe MI, Potet F, Bogomoletz WV, Dawson PA, Fabiani B, Chauveinc P, Fenzy A, Gazzard B, Goldfain D, Zeegen R. Incomplete sulphomucin-secreting intestinal metaplasia for gastric cancer. Preliminary data from a prospective study from three centres. Gut. 1985;26:1319-1326.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 138]  [Cited by in F6Publishing: 149]  [Article Influence: 3.8]  [Reference Citation Analysis (0)]
12.  Zhang XH, Bu YH, Wang JL, Yan X, Mi JM, Zhao WY, Zhang ZG, Yang YB. Follow up observation of gastric mucosal changes in subjects with abnormal PG levels. Zhongguo Zhongliu Linchuang. 2000;27:491-494.  [PubMed]  [DOI]  [Cited in This Article: ]
13.  Testino G, Cornaggia M, De Iaco F, Gada D. Is it possible with an immunophenotypic study to foresee the oncologic risk of epithelial gastric dysplasia? Hepatogastroenterology. 2002;49:601-603.  [PubMed]  [DOI]  [Cited in This Article: ]
14.  Karita M, Noriyasu A, Kosako E, Teramukai S, Matsumoto S. Relationship between pepsinogen I& amp; II and H. pylori infection considered with grade of atrophy and gastroduodenal diseases. Dig Dis Sci. 2003;48:1839-1845.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 3]  [Cited by in F6Publishing: 3]  [Article Influence: 0.1]  [Reference Citation Analysis (0)]
15.  Fernández R, Vizoso F, Rodríguez JC, Merino AM, González LO, Quintela I, Andicoechea A, Truan N, Díez MC. Expression and prognostic significance of pepsinogen C in gastric carcinoma. Ann Surg Oncol. 2000;7:508-514.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 17]  [Cited by in F6Publishing: 21]  [Article Influence: 0.9]  [Reference Citation Analysis (0)]
16.  Ohata H, Kitauchi S, Yoshimura N, Mugitani K, Iwane M, Nakamura H, Yoshikawa A, Yanaoka K, Arii K, Tamai H. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer. 2004;109:138-143.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 354]  [Cited by in F6Publishing: 361]  [Article Influence: 18.1]  [Reference Citation Analysis (0)]
17.  Haruma K, Komoto K, Kamada T, Ito M, Kitadai Y, Yoshihara M, Sumii K, Kajiyama G. Helicobacter pylori infection is a major risk factor for gastric carcinoma in young patients. Scand J Gastroenterol. 2000;35:255-259.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 58]  [Cited by in F6Publishing: 56]  [Article Influence: 2.3]  [Reference Citation Analysis (0)]
18.  Ohkuma K, Okada M, Murayama H, Seo M, Maeda K, Kanda M, Okabe N. Association of Helicobacter pylori infection with atrophic gastritis and intestinal metaplasia. J Gastroenterol Hepatol. 2000;15:1105-1112.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 45]  [Cited by in F6Publishing: 49]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
19.  Lee SA, Kang D, Shim KN, Choe JW, Hong WS, Choi H. Effect of diet and Helicobacter pylori infection to the risk of early gastric cancer. J Epidemiol. 2003;13:162-168.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 116]  [Cited by in F6Publishing: 120]  [Article Influence: 5.7]  [Reference Citation Analysis (0)]
20.  Basso D, Gallo N, Zambon CF, Navaglia F, Stockreiter E, Di Mario F, Rugge M, Plebani M. Different effects of H. pylori water extracts on cytokines, pepsinogen C and gastrin mucosal release in patients with or without duodenal ulcer. J Med. 2001;32:97-112.  [PubMed]  [DOI]  [Cited in This Article: ]
21.  Bodger K, Wyatt JI, Heatley RV. Variation in serum pepsinogens with severity and topography of Helicobacter pylori-associated chronic gastritis in dyspeptic patients referred for endoscopy. Helicobacter. 2001;6:216-224.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 47]  [Cited by in F6Publishing: 47]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
22.  Kikuchi S, Kurosawa M, Sakiyama T, Tenjin H, Miki K, Wada O, Inaba Y. Long-term effect of Helicobacter pylori infection on serum pepsinogens. Jpn J Cancer Res. 2000;91:471-476.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 18]  [Cited by in F6Publishing: 21]  [Article Influence: 0.9]  [Reference Citation Analysis (0)]
23.  Kishi K, Kinoshita Y, Matsushima Y, Okada A, Maekawa T, Kawanami C, Watanabe N, Chiba T. Pepsinogen C gene product is a possible growth factor during gastric mucosal healing. Biochem Biophys Res Commun. 1997;238:17-20.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 12]  [Cited by in F6Publishing: 12]  [Article Influence: 0.4]  [Reference Citation Analysis (0)]
24.  Sato Y, Iwafuchi M, Ueki J, Yoshimura A, Mochizuki T, Motoyama H, Sugimura K, Honma T, Narisawa R, Ichida T. Gastric carcinoid tumors without autoimmune gastritis in Japan: a relationship with Helicobacter pylori infection. Dig Dis Sci. 2002;47:579-585.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 36]  [Cited by in F6Publishing: 40]  [Article Influence: 1.8]  [Reference Citation Analysis (0)]
25.  Furuta T, El-Omar EM, Xiao F, Shirai N, Takashima M, Sugimura H. Interleukin 1beta polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. Gastroenterology. 2002;123:92-105.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 258]  [Cited by in F6Publishing: 253]  [Article Influence: 11.5]  [Reference Citation Analysis (0)]
26.  Milutinovic AS, Todorovic V, Milosavljevic T, Micev M, Spuran M, Drndarevic N. Somatostatin and D cells in patients with gastritis in the course of Helicobacter pylori eradication: a six-month, follow-up study. Eur J Gastroenterol Hepatol. 2003;15:755-766.  [PubMed]  [DOI]  [Cited in This Article: ]
27.  Kuwahara Y, Kono S, Eguchi H, Hamada H, Shinchi K, Imanishi K. Relationship between serologically diagnosed chronic atrophic gastritis, Helicobacter pylori, and environmental factors in Japanese men. Scand J Gastroenterol. 2000;35:476-481.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 26]  [Cited by in F6Publishing: 28]  [Article Influence: 1.2]  [Reference Citation Analysis (0)]
28.  Backert S, Schwarz T, Miehlke S, Kirsch C, Sommer C, Kwok T, Gerhard M, Goebel UB, Lehn N, Koenig W. Functional analysis of the cag pathogenicity island in Helicobacter pylori isolates from patients with gastritis, peptic ulcer, and gastric cancer. Infect Immun. 2004;72:1043-1056.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 99]  [Cited by in F6Publishing: 107]  [Article Influence: 5.4]  [Reference Citation Analysis (0)]
29.  Kuniyasu H, Kitadai Y, Mieno H, Yasui W. Helicobactor pylori infection is closely associated with telomere reduction in gastric mucosa. Oncology. 2003;65:275-282.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 27]  [Cited by in F6Publishing: 29]  [Article Influence: 1.5]  [Reference Citation Analysis (0)]